This report analyzes the merger and acquisition (M&A) activity in Q2 2026 in the Pharma sector.
In Q2 2026, global pharma deal value rose to $101.5 billion, an 84.2% increase from Q1 2026. Deal volume also inched up 4.2%, with 124 M&A transactions. Oncology emerged as the leading therapeutic area recording 44 deals.
In Q2 2026, global pharma deal value rose to $101.5 billion, an 84.2% increase from Q1 2026. Deal volume also inched up 4.2%, with 124 M&A transactions. Oncology emerged as the leading therapeutic area recording 44 deals.
Scope
- This report provides an overview of M&A activity globally in Q2 2026 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q2 2026 in the Pharma sector.
Reasons to Buy
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Sun Pharmaceutical Industries
- Organon
- Merck
- Bio-Techne Corp
- AbbVie
- Apogee Therapeutics
- GSK
- Nuvalent
- Eli Lilly
- Kelonia Therapeutics
- Gilead Sciences
- Tubulis
- Angelini Pharma
- Catalyst Pharmaceuticals
- Neurocrine Biosciences
- Soleno Therapeutics
- Bayer
- Perfuse Therapeutics
- Eli Lilly
- Ajax Therapeutics
